Summary
CYP2J2 inhibitors are compounds that reduce the activity of the CYP2J2 enzyme, which can reduce drug metabolism, potentially impacting the effects of drug therapy.
CYP2J2 is a cytochrome P450 (CYP) enzyme that makes up less than 1% of total cytochrome P450 enzymes in the liver. Rather, CYP2J2 is expressed in high levels in the heart. CYP2J2 is involved in the metabolism of any medications that are CYP2J2 substrates. CYP2J2 inducers can reduce the body’s metabolism of any such medications, although there are currently very few medications that are known to rely on CYP2J2 for metabolism.[1]
The table below outlines some of the most common or clinically relevant CYP2J2 inhibitors.[2][1][3] Importantly, this list is not exhaustive.
| CYP2J2 Inhibitors |
|---|
| Ketoconazole |
References
- ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
- ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
- ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)